Cue Biopharma, Inc. (CUE) News
Filter CUE News Items
CUE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest CUE News From Around the Web
Below are the latest news stories about CUE BIOPHARMA INC that investors may wish to consider to help them evaluate CUE as an investment opportunity.
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced the grant of an inducement option award to its newly appointed interim chief development officer, Daniel Baker, M.D. The grant was approved by a majority of the independent directors of the Compa |
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare ConferenceBOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced today that it will take part in an unplugged fireside discussion at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY, Dec 3-5, 2024. During the fireside discussion, Cue Biopharma |
Cue Biopharma Third Quarter 2024 Earnings: Beats ExpectationsCue Biopharma ( NASDAQ:CUE ) Third Quarter 2024 Results Key Financial Results Revenue: US$3.34m (up 59% from 3Q 2023... |
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue EstimatesCue Biopharma (CUE) delivered earnings and revenue surprises of 15% and 205.22%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business HighlightsBOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today provided a business and financial update for the third quarter of 2024. Recent Business Highlights Presented positive updated data from the Phase 1 trials of CUE-101 and CUE-102 at the Society for Immunotherapy o |
Cue Biopharma Announces Strategic Organizational TransitionDaniel Baker, M.D., will join Cue Biopharma’s executive team as interim chief development officer (CDO), effective Monday, November 25, 2024Anish Suri, Ph.D., president & chief scientific officer (CSO) of Cue Biopharma, to transition to principal research and immunology advisor BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific |
Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare ConferenceBOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced today that it will take part in a fireside chat at the Stifel 2024 Healthcare Conference being held in New York, NY, November 18-19, 2024. During the fireside chat, Cue Biopharma will highlight current update |
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual MeetingObjective response rate (ORR) of 46%, 12-month overall survival (OS) of 91.3% and a median overall survival (mOS) of 21.8 months in first line (1L) HPV+ R/M HNSCC patients treated with CUE-101 and KEYTRUDA® (pembrolizumab)ORR of 50% in 1L patients treated with CUE-101 and pembrolizumab with low PD-L1 expression (combined positive score (CPS) 1-19) 67% overall disease control rate (DCR) in late-stage pancreatic cancer patients treated with CUE-102 monotherapy, including an unconfirmed partial res |
Cue Biopharma (NASDAQ:CUE) adds US$31m to market cap in the past 7 days, though investors from three years ago are still down 89%This month, we saw the Cue Biopharma, Inc. ( NASDAQ:CUE ) up an impressive 135%. But that is meagre solace in the face... |
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingBOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced it will deliver an oral and a poster presentation on the company’s Immuno-STAT™ clinical assets CUE-101 and CUE-102, representative of the CUE-100 series, at the Society for Immunotherapy of Cancer’s 39th Annual Meeting (SITC 2024). The conference will |